Sourav Santra - Sarepta Therapeut Inc

基本信息

浏览量：0

职业迁徙

个人简介

Ph.D. Research Scholar (English), C.V. Raman Global University, Bhubaneswar, Odisha, India

研究兴趣

论文共 46 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

P31 Interim Analysis of EVOLVE: Evaluating Eteplirsen, Golodirsen, or Casimersen Treatment in Patients <7 Years Old in Routine Clinical Practice

S. Grabich,S. Santra,M. Waldrop,K. Mathews,F. Abid,L. Ramos-Platt,R. Scharf,C. Zaidman,I. Sehinovych,C. McDonald

Neuromuscular Disorders (2023): S104-S105

引用0浏览0引用

Improving longitudinally in rare disease data capture in real-world evidence combining clinical trials and observational data: A case study using EVOLVE

Shannon Grabich,Kristen Ricchetti-Masterson,Sourav Santra, Shane Hornibrook, David Miller

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY（2023）

引用0浏览0引用

Interim Analysis of EVOLVE: A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

K. Ricchetti-Masterson,S. Santra, S. Hornibrook,B. Byrne, A. Kumar,K. Mathews,L. Ramos-Platt,M. Waldrop,C. Zaidman,I Sehinovych, D. Miller, N. Hasan,C. McDonald

NEUROMUSCULAR DISORDERS (2023): S32-S32

引用0浏览0引用

Evaluation of Raavrh74 Gene Therapy Vector Seroprevalence by Measurement of Total Binding Antibodies in Patients with Duchenne Muscular Dystrophy

Natalie L. L. Goedeker, Sachi D. D. Dharia,Danielle A. A. Griffin, Jesantha Coy, Todd Truesdale, Rajan Parikh, Kasen Whitehouse,Sourav Santra,Damon R. R. Asher,Craig M. M. Zaidman

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS（2023）

引用5浏览0WOS引用

A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment

Olga Mitelman,Hoda Z. Abdel-Hamid,Barry J. Byrne,Anne M. Connolly,Peter Heydemann,Crystal Proud,Perry B. Shieh,Kathryn R. Wagner,Ashish Dugar,Sourav Santra,James Signorovitch,Nathalie Goemans,Craig M. McDonald,Eugenio Mercuri,Jerry R. Mendell

Journal of neuromuscular diseases（2022）

引用18浏览0WOS引用

Meta-Analysis of Drug Safety Assessment

Rositsa B. Dimova,Sourav Santra, Melvin Munsaka

Quantitative Drug Safety and Benefit-Risk Evaluationpp.187-212, (2021)

引用0浏览0引用

Natalizumab Versus Fingolimod for Patients with Active Relapsing-Remitting Multiple Sclerosis: Results from REVEAL, a Prospective, Randomised Head-to-head Study

Helmut Butzkueven,Stephanie Licata,Douglas Jeffery,Douglas L. Arnold,Massimo Filippi,Jeroen J. G. Geurts,Sourav Santra,Nolan Campbell,Pei-Ran Ho

BMJ open（2020）

引用14浏览0WOS引用

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

Jai Perumal,Robert J. Fox,Roumen Balabanov,Laura J. Balcer,Steven Galetta,Shavy Makh,Sourav Santra,Christophe Hotermans,Lily Lee

BMC Neurol（2019）

引用36浏览0WOS引用

Evaluation of changes in cognitive function as assessed by NeuroTrax in patients with multiple sclerosis treated with natalizumab for up to 5 years

M. Gudesblatt,J. Srinivasan, C. LaBozzetta,J. Wilken,M. Zarif,B. Bumstead,L. Fafard,K. Blitz,M. Buhse,S. Santra,C. Hotermans,L. Lee

MULTIPLE SCLEROSIS JOURNAL（2018）

引用0浏览0引用

Natalizumab is associated with no evidence of disease activity and improved cognitive function and health-related quality of life in anti-JC virus seronegative patients with early relapsing-remitting multiple sclerosis: a 3-year analysis of STRIVE

J. Perumal,R. J. Fox,R. Balabanov,L. Balcer,S. Galetta, C. Schroder,S. Santra,C. Hotermans,L. Lee

MULTIPLE SCLEROSIS JOURNAL（2018）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn